Drug
M1774
M1774: highest development phase Phase 1, developed by Merck KGaA. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Merck KGaA
Trials
| Drug | Phase | Indication |
|---|---|---|
| M1774 NCT04170153 | Phase 1 | Metastatic or Locally Advanced Unresectable Solid Tumors |
Latest
No recent events.
Follow M1774 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.